NCT03096405

Brief Summary

Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM). With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse. The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2014

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2016

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2017

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

March 25, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 30, 2017

Completed
Last Updated

May 30, 2017

Status Verified

March 1, 2017

Enrollment Period

2.2 years

First QC Date

March 25, 2017

Last Update Submit

May 24, 2017

Conditions

MRSA Bacteremia

Outcome Measures

Primary Outcomes (1)

  • Adaptation duration of antibiotherapy

    24 hours

Secondary Outcomes (2)

  • Mortality

    Day 30

  • average duration of hospitalization

    day 30

Interventions

Polymerase Chain Reaction of Methicillin Resistant Staphyloccus AureusDIAGNOSTIC_TEST

Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

every patient hospitalized in St Joseph Hospital with an positive hemoculture to Staphylococcus Aureus Methicillin Sensitive

You may qualify if:

  • Hemoculture positive to Staphylococcus Aureus Methicillin Sensitive

You may not qualify if:

  • Positive test to Staphylococcus Aureus Methicillin Sensitive but not hospitalized.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Groupe Hospitalier Paris Saint Joseph

Paris, Île-de-France Region, 75014, France

Location

Study Officials

  • MIZRAHI Assaf, MD

    Groupe Hospitalier Paris St JOSEPH

    PRINCIPAL INVESTIGATOR

  • LEMONNIER Alban, MD

    Groupe Hospitalier Paris St JOSEPH

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2017

First Posted

March 30, 2017

Study Start

February 1, 2014

Primary Completion

March 31, 2016

Study Completion

February 28, 2017

Last Updated

May 30, 2017

Record last verified: 2017-03

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)